Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Breast Cancer

Free Subscription Articles published in Nat Rev Clin Oncol Retrieve available abstracts of 19 articles: HTML format

Single Articles

February 2026
1. KILLOCK D
   CDK4/6 inhibition provides additional efficacy in HER2(+), HR(+) breast cancer.
   Nat Rev Clin Oncol. 2026 Feb 17. doi: 10.1038/s41571-026-01133.
   PubMed    
   
   
   
2. LOBO-MARTINS S, Luen SJ, Piccart M, Loi S, et al
   Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.
   Nat Rev Clin Oncol. 2026 Feb 3. doi: 10.1038/s41571-026-01120.
   PubMed     Abstract available
   
   
   November 2025
3. KILLOCK D
   T-DXd shows promise in neoadjuvant therapy for HER2(+) breast cancer.
   Nat Rev Clin Oncol. 2025 Nov 10. doi: 10.1038/s41571-025-01103.
   PubMed    
   
   
   
4. FEHM T, Neubauer H
   Intervening on dormancy to prevent breast cancer recurrence.
   Nat Rev Clin Oncol. 2025 Nov 3. doi: 10.1038/s41571-025-01087.
   PubMed    
   
   
   August 2025
5. KILLOCK D
   ASTER 70 suggests no clinical benefit from adjuvant chemotherapy in older patients with ER(+)HER2(-) breast cancer.
   Nat Rev Clin Oncol. 2025 Aug 18. doi: 10.1038/s41571-025-01070.
   PubMed    
   
   
   July 2025
6. NEVEN P, Han SN
   PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER(+)HER2(-) breast cancer harbouring acquired ESR1 mutations.
   Nat Rev Clin Oncol. 2025 Jul 22. doi: 10.1038/s41571-025-01062.
   PubMed    
   
   
   June 2025
7. CARLETON N, McAuliffe PF
   Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring.
   Nat Rev Clin Oncol. 2025 Jun 9. doi: 10.1038/s41571-025-01040.
   PubMed    
   
   
   
8. ROBBINS CJ, Bates KM, Rimm DL
   HER2 testing: evolution and update for a companion diagnostic assay.
   Nat Rev Clin Oncol. 2025;22:408-423.
   PubMed     Abstract available
   
   
   January 2025
9. SIDAWAY P
   Women with clinically node negative breast cancer can safely avoid axillary surgery.
   Nat Rev Clin Oncol. 2025 Jan 3. doi: 10.1038/s41571-024-00982.
   PubMed    
   
   
   November 2024
10. KILLOCK D
    First-line triplet therapy for advanced-stage PIK3CA-mutant HR(+) breast cancer improves outcomes.
    Nat Rev Clin Oncol. 2024 Nov 12. doi: 10.1038/s41571-024-00968.
    PubMed    
    
    
    
11. DRAGO J, Modi S
    Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
    Nat Rev Clin Oncol. 2024 Nov 6. doi: 10.1038/s41571-024-00963.
    PubMed    
    
    
    
12. WAKS AG, Martinez-Saez O, Tarantino P, Braso-Maristany F, et al
    Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.
    Nat Rev Clin Oncol. 2024;21:818-832.
    PubMed     Abstract available
    
    
    August 2024
13. LLOYD MR, Jhaveri K, Kalinsky K, Bardia A, et al
    Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.
    Nat Rev Clin Oncol. 2024 Aug 23. doi: 10.1038/s41571-024-00935.
    PubMed     Abstract available
    
    
    
14. MARRA A, Chandarlapaty S, Modi S
    Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
    Nat Rev Clin Oncol. 2024 Aug 2. doi: 10.1038/s41571-024-00933.
    PubMed    
    
    
    July 2024
15. YOON J, Oh DY
    HER2-targeted therapies beyond breast cancer - an update.
    Nat Rev Clin Oncol. 2024 Jul 22. doi: 10.1038/s41571-024-00924.
    PubMed     Abstract available
    
    
    June 2024
16. KILLOCK D
    ALND can be safely omitted for patients with sentinel-node macrometastases.
    Nat Rev Clin Oncol. 2024;21:402.
    PubMed    
    
    
    May 2024
17. DIECI MV, Guarneri V
    Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain.
    Nat Rev Clin Oncol. 2024 May 22. doi: 10.1038/s41571-024-00907.
    PubMed    
    
    
    April 2024
18. SIDAWAY P
    KN046 shows tolerability and activity in TNBC.
    Nat Rev Clin Oncol. 2024;21:251.
    PubMed    
    
    
    March 2024
19. KONTOS D
    The promise of AI in personalized breast cancer screening: are we there yet?
    Nat Rev Clin Oncol. 2024 Mar 12. doi: 10.1038/s41571-024-00877.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum